Patient reported outcomes in subjects with type 2 diabetes treated with monotherapy regimens of once-daily human GLP-1 analogue liraglutide or glimepiride

被引：0

作者：

Bode, B. W. ^{[1
]}

Hale, P. M. ^{[2
]}

Hammer, M. ^{[3
]}

Testa, M. A. ^{[4
]}

Garber, A. ^{[5
]}

机构：

[1] Atlanta Diabet Associates, Atlanta, GA USA

[2] Novo Nordisk Inc, Princeton, NJ USA

[3] Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark

[4] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA

[5] Baylor Coll Med, Houston, TX 77030 USA

来源：

DIABETOLOGIA | 2008年 / 51卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

894

引用

页码：S357 / S358

页数：2

共 50 条

[21] The once-daily human GLP-1 analog liraglutide reduces body weight in subjects with type 2 diabetes, irrespective of body mass index at baseline
Russell-Jones, David
Shaw, Jonathan E.
Brandle, Michael
Matthews, David
Frid, Anders
Zdravkovic, Milan
Schmitz, Ole
DIABETES, 2008, 57 : A593 - A594
[22] The once-daily human GLP-1 analog-liraglutide reduces systolic blood pressure in patients with type 2 diabetes
Colagiuri, Steven
Frid, Anders
Zdravkovic, Milan
Le-Thi, Tu Duyen
Vaag, Allan
DIABETES, 2008, 57 : A164 - A165
[23] The once-daily human GLP-1 analogue liraglutide impacts appetite and energy intake in patients with type 2 diabetes after short-term treatment
Flint, A.
Kapitza, C.
Zdravkovic, M.
DIABETES OBESITY & METABOLISM, 2013, 15 (10): : 958 - 962
[24] Liraglutide, a human GLP-1 analogue, reduces systolic blood pressure in subjects with type 2 diabetes
Colagiuri, S.
Frid, A.
Zdravkovic, M.
Le-Thi, T. D.
Vaag, A.
Garber, A.
Zinman, B.
DIABETOLOGIA, 2008, 51 : S359 - S360
[25] Liraglutide, a once-daily human GLP-1 analog, reduces fat percentage, visceral and subcutaneous adipose tissue and hepatic steatosis compared with glimepiride when added to metformin in subjects with type 2 diabetes
Jendle, Johan
Nauck, Michael A.
Matthews, David
Frid, Anders
Hermansen, Kjeld
Duering, Maria
Zdravkovic, Milan
Strauss, Boyd J.
DIABETES, 2008, 57 : A32 - A33
[26] Liraglutide, a once-daily human GLP-1 analog, in type 2 diabetes provides similar glycemic control with reduced body weight compared with glimepiride when added to metformin
Nauck, Michael A.
Frid, Anders
Hermansen, Kjeld
Shah, Nalini S.
Tankova, Tsvetalina
Mitha, Ismail H.
During, Maria
Zdravkovic, Milan
Matthews, David
DIABETES, 2008, 57 : A150 - A150
[27] Erratum: Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analogue, liraglutide
A Astrup
R Carraro
N Finer
A Harper
M Kunesova
M E J Lean
L Niskanen
M F Rasmussen
A Rissanen
S Rössner
M J Savolainen
L Van Gaal
International Journal of Obesity, 2012, 36 : 890 - 890
[28] The once-daily human GLP-1 analogue, liraglutide, significantly reduces markers of cardiovascular risk in type 2 diabetes: a meta-analysis of six clinical trials
Plutzky, J.
Garber, A. J.
Falahati, A.
Toft, A. D.
Poulter, N. R.
EUROPEAN HEART JOURNAL, 2009, 30 : 917 - 917
[29] Meta-analysis demonstrates that liraglutide, a once-daily human GLP-1 analogue, significantly reduces lipids and other markers of cardiovascular risk in type 2 diabetes
Plutzky, J.
Garber, A.
Toft, A. D.
Poulter, N. R.
DIABETOLOGIA, 2009, 52 : S299 - S300
[30] Treatment satisfaction in patients with type 2 diabetes is significantly improved with liraglutide, the once-daily GLP-1 analogue versus sitagliptin, both combined with metformin
Montanya Mias, E.
Cuddihy, R.
Pratley, R.
Hammer, M.
Thomsen, A.
Davies, M. J.
DIABETOLOGIA, 2010, 53

← 1 2 3 4 5 →